425: Passage Bio and Remix Therapeutics Merger

Passage Bio and Remix Therapeutics have entered into a definitive merger agreement to combine in an all-stock transaction, with the combined company focusing on Remix's RNA-targeted small molecule pipeline.

Summary

• Passage Bio and Remix Therapeutics will combine in an all-stock transaction, with the combined company operating as Remix Therapeutics, Inc.
• Remix stockholders are expected to own approximately 93% of the combined company, while pre-merger Passage Bio shareholders are expected to own approximately 7% (subject to net cash adjustments).
• Remix has secured a concurrent oversubscribed private placement financing of at least $100 million.
• The combined company expects to have sufficient cash to fund operations into 2028.
• Passage Bio shareholders will receive a Contingent Value Right (CVR) representing the right to receive payments from certain existing license agreements.
• Passage Bio is terminating its gene therapy programs, including PBFT02, and its agreements with Catalent and the University of Pennsylvania related to those programs.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive development for Remix stakeholders, providing a path to public markets and capital, while it represents a significant pivot and dilution for Passage Bio shareholders.

Positives

• The combined company is expected to be well-capitalized with a cash runway into 2028.
• The merger includes a $100 million concurrent private placement financing.
• Remix's lead program, REM-422, is a clinical-stage, orally available mRNA degrader targeting MYB.
• The transaction provides Passage Bio shareholders with a CVR for potential future proceeds from legacy assets.
• The combined company will be led by Remix's existing management team.

Negatives

• Passage Bio shareholders will experience significant dilution, owning only approximately 7% of the combined company.
• Passage Bio is winding down its existing gene therapy programs, including PBFT02.
• The CVRs are non-transferable, will not be listed on any exchange, and there is no assurance that any payments will be made.
• The merger is subject to various closing conditions, including stockholder approval and regulatory clearances.

Risks

• The proposed transaction may not be consummated on the anticipated terms or at all.
• The combined company will require substantial additional capital to finance future operations beyond 2028.
• Clinical trials for REM-422 may not demonstrate sufficient safety or efficacy to obtain regulatory approval.
• The combined company may fail to realize the anticipated benefits of the merger.
• The CVR holders may never receive any payments under the CVR agreement.
• The concurrent private placement financing may not be consummated.

Future Outlook

The combined company intends to advance Remix's pipeline of RNA-targeted small molecule therapies, specifically focusing on REM-422, with clinical readouts expected in 2027 and operations funded into 2028.

Management Comments

• Peter Smith, Ph.D., CEO of Remix: 'This transaction marks a transformative step for Remix as we advance our mission to reprogram RNA processing and unlock a new class of medicines.'
• Will Chou, M.D., CEO of Passage Bio: 'Following a thorough evaluation of strategic alternatives, we are thrilled to have identified Remix as the ideal partner for this transaction.'

Industry Context

StockSavvy.ai notes that this merger follows a trend of clinical-stage biotech companies seeking strategic alternatives or reverse mergers to extend cash runways and focus on high-potential assets in the face of challenging capital markets.

Comparison to Industry Standards

• The all-stock merger structure is common for biotech companies seeking to combine pipelines and preserve cash.
• The use of a CVR to monetize legacy assets is a standard mechanism in biotech M&A to bridge valuation gaps.
• The concurrent private placement (PIPE) is a standard requirement for many biotech mergers to ensure the combined entity is well-capitalized.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• None disclosed.

Stakeholder Impact

• Passage Bio shareholders will be significantly diluted.
• Remix stockholders will gain access to public markets.
• Employees of Passage Bio may be impacted by the wind-down of gene therapy programs.

Next Steps

• File Form S-4 registration statement with the SEC.
• Obtain stockholder approvals from both Passage Bio and Remix.
• Obtain Nasdaq listing approval for the combined company.
• Close the concurrent private placement financing.
• Complete the merger transaction, expected in the fourth quarter of 2026.

Key Dates

Recommendation

The merger represents a significant change in business direction for Passage Bio. Investors should wait for the S-4 filing to understand the full financial implications and the progress of the combined company's clinical programs.

Keywords

Merger, Biotechnology, RNA processing, Oncology, Private placement, Passage Bio, Remix Therapeutics, REM-422